Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 01 2019
Historique:
received: 05 11 2017
accepted: 20 12 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 21 3 2019
Statut: epublish

Résumé

Despite significant progress, our understanding of how specific oncogenes transform cells is still limited and likely underestimates the complexity of downstream signalling events. To address this gap, we use mass spectrometry-based chemical proteomics to characterize the global impact of an oncogene on the expressed kinome, and then functionally annotate the regulated kinases. As an example, we identify 63 protein kinases exhibiting altered expression and/or phosphorylation in Src-transformed mammary epithelial cells. An integrated siRNA screen identifies nine kinases, including SGK1, as being essential for Src-induced transformation. Accordingly, we find that Src positively regulates SGK1 expression in triple negative breast cancer cells, which exhibit a prominent signalling network governed by Src family kinases. Furthermore, combined inhibition of Src and SGK1 reduces colony formation and xenograft growth more effectively than either treatment alone. Therefore, this approach not only provides mechanistic insights into oncogenic transformation but also aids the design of improved therapeutic strategies.

Identifiants

pubmed: 30655532
doi: 10.1038/s41467-018-08154-1
pii: 10.1038/s41467-018-08154-1
pmc: PMC6336867
doi:

Substances chimiques

Antineoplastic Agents 0
Benzodioxoles 0
Immediate-Early Proteins 0
Quinazolines 0
RNA, Small Interfering 0
saracatinib 9KD24QGH76
src-Family Kinases EC 2.7.10.2
Protein Serine-Threonine Kinases EC 2.7.11.1
serum-glucocorticoid regulated kinase EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296

Références

Nature. 1995 Feb 9;373(6514):536-9
pubmed: 7845468
Mol Cell. 2008 Aug 8;31(3):438-48
pubmed: 18691976
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
EMBO J. 2014 Jun 2;33(11):1227-42
pubmed: 24797473
Proc Natl Acad Sci U S A. 1978 Sep;75(9):4102-6
pubmed: 212733
Oncogene. 2008 Apr 24;27(19):2693-704
pubmed: 17998934
Cancer Res. 2009 Mar 15;69(6):2279-86
pubmed: 19276381
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
J Proteome Res. 2008 Aug;7(8):3447-60
pubmed: 18563927
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
Biochem J. 2013 Jun 15;452(3):499-508
pubmed: 23581296
J Am Soc Nephrol. 2010 May;21(5):811-8
pubmed: 20338997
BMC Cancer. 2010 Feb 12;10:41
pubmed: 20152043
Cancer Res. 2005 Feb 15;65(4):1335-42
pubmed: 15735019
EMBO J. 2009 Apr 8;28(7):843-53
pubmed: 19214184
Biochem J. 2005 Oct 15;391(Pt 2):359-70
pubmed: 15975092
Pharmacol Ther. 2015 Feb;146:132-49
pubmed: 25316657
Nat Struct Mol Biol. 2010 Feb;17(2):216-21
pubmed: 20118938
Cancer Cell. 2016 Aug 8;30(2):229-242
pubmed: 27451907
EMBO J. 1998 Aug 3;17(15):4346-57
pubmed: 9687503
Growth Factors. 2010 Dec;28(6):394-408
pubmed: 20919962
Mol Cell. 2009 Jul 10;35(1):11-25
pubmed: 19595712
J Clin Pathol. 2011 Jul;64(7):578-86
pubmed: 21490376
Nat Rev Cancer. 2016 Feb;16(2):83-98
pubmed: 26822576
ChemMedChem. 2017 Jun 21;12(12):954-961
pubmed: 28334506
Cancer. 2002 Jan 15;94(2):344-51
pubmed: 11900220
Nucleic Acids Res. 2013 Jan;41(Database issue):D808-15
pubmed: 23203871
Mol Cell Proteomics. 2012 Aug;11(8):355-69
pubmed: 22499769
PLoS One. 2016 Mar 29;11(3):e0152300
pubmed: 27023625
Sci Rep. 2017 Mar 31;7:45545
pubmed: 28361970
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Cell Sci. 2004 Mar 1;117(Pt 7):989-98
pubmed: 14996930
J Proteome Res. 2013 Jul 5;12(7):3104-16
pubmed: 23692254
Proteomics. 2015 Jan;15(2-3):232-44
pubmed: 25403792
Crit Rev Oncog. 2012;17(2):145-59
pubmed: 22471705
Oncogene. 2014 Sep 11;33(37):4537-47
pubmed: 24121272
Virology. 2007 Jul 20;364(1):10-20
pubmed: 17448514
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Cell Sci. 2012 Oct 1;125(Pt 19):4423-33
pubmed: 23132929
J Cell Physiol. 2007 Feb;210(2):436-44
pubmed: 17096371
Nat Biotechnol. 2005 Jan;23(1):94-101
pubmed: 15592455
Am J Pathol. 2007 Jan;170(1):366-76
pubmed: 17200208
Oncotarget. 2017 Aug 7;8(41):70736-70751
pubmed: 29050315
Biochem Biophys Res Commun. 2017 Aug 26;490(3):650-656
pubmed: 28634071
Oncogene. 2002 Oct 17;21(47):7256-65
pubmed: 12370817
PLoS One. 2012;7(5):e37803
pubmed: 22662228
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
Mol Cancer Ther. 2010 Aug;9(8):2322-32
pubmed: 20682659
Cancer Res. 2010 Nov 15;70(22):9391-401
pubmed: 20861192
J Pediatr Endocrinol Metab. 2018 Mar 28;31(3):331-338
pubmed: 29360628
FASEB J. 2010 Jun;24(6):1637-48
pubmed: 20071654
Cancer Res. 2013 Mar 15;73(6):1969-80
pubmed: 23378338
PeerJ. 2013 Aug 08;1:e126
pubmed: 23940838
Pharmacol Res. 2015 Apr;94:9-25
pubmed: 25662515
Curr Opin Cell Biol. 2006 Oct;18(5):516-23
pubmed: 16919435
Mol Cell Proteomics. 2007 Mar;6(3):537-47
pubmed: 17192257
J Biol Chem. 2016 Oct 7;291(41):21571-21583
pubmed: 27531744

Auteurs

Xiuquan Ma (X)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Luxi Zhang (L)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Jiangning Song (J)

Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.
Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Monash Centre for Data Science, Faculty of Information Technology, Monash University, Melbourne, VIC, 3800, Australia.

Elizabeth Nguyen (E)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Rachel S Lee (RS)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Samuel J Rodgers (SJ)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Fuyi Li (F)

Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.
Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.

Cheng Huang (C)

Monash Biomedical Proteomics Facility and Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.

Ralf B Schittenhelm (RB)

Monash Biomedical Proteomics Facility and Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.

Howard Chan (H)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Chanly Chheang (C)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Jianmin Wu (J)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Centre for Cancer Bioinformatics, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Kristin K Brown (KK)

Cancer Therapeutics Program and Cancer Metabolism Program, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
Department of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3010, Australia.

Christina A Mitchell (CA)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia.

Kaylene J Simpson (KJ)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.

Roger J Daly (RJ)

Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia. roger.daly@monash.edu.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, 3800, Australia. roger.daly@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH